Categorynews

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

May 29, 2019 Off By BusinessWire

Obesity is a complex disease and leading cause of morbidity and
mortality and there are only insufficient treatment options available
New collaboration aims to develop novel peptide poly-agonists for the
treatment of obesity and concomitant diseases
Gubra may receive up to EUR 240 million in upfront and success-based
development and commercialization milestones plus staggered up to
double-digit royalties on worldwide net sales

INGELHEIM, Germany & HØRSHOLM, Denmark–(BUSINESS WIRE)–Boehringer Ingelheim and Gubra announce a second collaboration and
license agreement for the development of novel poly-agonist peptides to
treat obesity. It will bring together Gubra’s established expertise in
the design, synthesis, pharmaceutical characterization and in vivo
testing of therapeutic peptides with Boehringer Ingelheim’s expertise in
the research and development of innovative medicines in cardiometabolic
diseases.

This second joint research and development program between Boehringer
Ingelheim and Gubra builds on a successful ongoing collaboration in the
obesity field, which was launched in 2017, and which has already
achieved important milestones. It contributes to the growing Boehringer
Ingelheim research and development stage portfolio in the obesity field.

“We look forward to expanding our productive collaboration with the
Gubra team,” said Clive R. Wood, Ph.D., Corporate Senior Vice President
Discovery Research at Boehringer Ingelheim. “I anticipate that these
programs will help us bring much needed new treatment options for
obesity patients.”

Boehringer Ingelheim has built a broad portfolio of marketed products
for thromboembolic diseases, type 2 diabetes, acute stroke and
myocardial infarction, hypertension and cardiovascular death risk
reduction. With its extensive experience in the field and commitment to
innovation, the company aims to transform the lives of people with
cardiometabolic diseases.

Henrik Blou, CEO of Gubra said, “We are very pleased to enter into a
second collaboration and license agreement with Boehringer Ingelheim
focusing on the treatment of obesity. It is important for Gubra to find
strong partners for our proprietary research programs, and our first
collaboration with Boehringer Ingelheim has shown that the strengths of
both companies are nicely complementary. Joining forces on this novel
research program has the potential to take obesity treatment to the next
level to the benefit of patients around the world.”

Please click on the link for “Notes to Editors” and “References”:

http://www.boehringer-ingelheim.com/press-release/new-collaboration-gubra-obesity-treatment